CME Symposium on Cardiovascular Risk Reduction and LDL-C: Evolving Perspectives

SPRINGFIELD, N.J. - March 22, 2018 - PRLog -- Cardiovascular Risk Reduction and LDL-C: Evolving Perspectives

Robert P. Giugliano, MD, SM
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Pamela Morris, MD
Nurse Scientist
Cedars-Sinai Heart Institute
Los Angeles, CA

Click to Register Online

Cardiovascular nurses play a critical role in managing patients with increased atherosclerotic cardiovascular disease (ASCVD) risk, and specifically, in patients with elevated LDL-Cholesterol (LDL-C). Their efforts at reducing ASCVD risk in patients with elevated LDL-C should be based on guideline-recommended use of statin therapy, up-to-date knowledge on clinical profiles of non-statin drugs, and awareness and implementation of updated pathways for the use of non-statin therapies for LDL-C lowering. In addition, through effective  communication, patient education, and shared decision-making, cardiovascular nurses can create activated, adherent patients. This educational initiative will explore, through state-of-the-art lecture and challenging cases of "real-world" patients, the use of non-statin therapies to reduce ASCVD risk in patients with elevated LDL-C.

This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). Multiple educational grants have been requested to support this program. PCNA is approved as a provider of nurse practitioner continuing education (CE) programs by the American Association of Nurse Practitioners (AANP), provider number 030602. This program is accredited for 1 contact hour of continuing education. This program was planned in accordance with AANP CE Policies and Commercial Support Standards.

This activity is supported by an educational donation provided by Amgen.

Pre-registration is for planning purposes only.
For additional CME activities and online CME courses, visit CMEPlanet.